

AGENUS INC  
Form 8-K  
November 09, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **November 9, 2012**

---

**AGENUS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**000-29089**  
(Commission File Number)

**06-1562417**  
(IRS Employer Identification No.)

**3 Forbes Road**  
**Lexington, MA**  
(Address of principal executive offices)

**02421**  
(Zip Code)

Registrant's telephone number, including area code: **781-674-4400**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

**Item 8.01. Other Events.**

Edgar Filing: AGENUS INC - Form 8-K

Agenus Inc. announced today the second complete set of results from the Phase 3 trial of GlaxoSmithKline's (NYSE: GSK) RTS,S malaria vaccine candidate (also known as Mosquirix<sup>™</sup>), which contains Agenus' QS-21 Stimulon adjuvant, were published online in the *New England Journal of Medicine* and announced at the International Vaccines for Africa Conference in Cape Town, South Africa. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S. When administered with standard childhood vaccines in the Phase 3 study<sup>1</sup>, efficacy of the RTS,S vaccine candidate against clinical and severe malaria in infants aged 6 to 12 weeks was 31% (clinical) and 37% (severe)<sup>2</sup> over 12 months of follow-up after the third vaccine dose.<sup>3</sup>

The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.1 to this current report on Form 8-K.

<sup>1</sup>Standard childhood vaccines used were the combined diphtheria-tetanus-whole-cell-pertussis, hepatitis B, and *Haemophilus influenzae* type b vaccine (DTPwHepB/Hib) and the oral polio virus vaccine (OPV)

<sup>2</sup>Based on According To Protocol (ATP) statistical methodology

<sup>3</sup>Average risk for malaria in the control group was 0.9 clinical episodes per child per year and 2.3% of the children experienced at least one episode of severe malaria

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is filed herewith:

99.1 Press Release dated November 9, 2012

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGENUS INC.**

(Registrant)

/s/ **GARO H. ARMEN**

Garro H. Armen  
*Chief Executive Officer*

**November 9, 2012**

(Date)

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated November 9, 2012